MacroGenics, Inc.

MGNX • Biotechnology

$4.40

▲ +0.15 (+3.53%)

Precio actual

ResultadosÚltimo reporte: 31 mar 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$279.18M

Crecimiento

-0.7%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Crecimiento positivo de ingresos · 17.0%Liquidez saludable · 5.1Rentabilidad débil

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 13 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 14 ago 2026, 12:57 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$4.40

Change3.53%

Shares Out63.45M

Market Cap$279.18M

Enterprise Value$161.46M

52W Range1.29 - 5.08

Beta1.22

P/E-3.97

P/S1.78

P/B13.17

P/FCF-3.89

EV/Sales1.03

Price$4.40

Change3.53%

Shares Out63.45M

Market Cap$279.18M

Enterprise Value$161.46M

52W Range1.29 - 5.08

Beta1.22

P/E-3.97

P/S1.78

P/B13.17

P/FCF-3.89

EV/Sales1.03

EV/EBITDA-2.85

EV/FCF-2.25

Earnings Yield-25.20%

FCF Yield-25.68%

Dividend Yield0.00%

Gross Margin71.12%

Oper. Margin-48.72%

Profit Margin-49.91%

Debt/Eq1.92

Current Ratio5.10

Quick Ratio4.92

Revenue 5Y-0.65%

Target$6.00

Target Upside36.36%

Target Median$6.00

Target Range6.00 - 6.00

Volume1.37M

Avg Volume1.04M

EPS Surprise-0.01

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

58/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

92/100

Por qué este puntaje▼

Crecimiento positivo de ingresos · 17.0%Liquidez saludable · 5.1Rentabilidad débil

Analyst view

Analyst sentiment and price target

MGNX

Analyst sentiment

Based on 22 analyst votes · 2026-09-05

75/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-14

Bajo

$6.00

Promedio

$6.00

Mediana

$6.00

Alto

$6.00

Resumen de la compañía

IPO: 10/10/2013

Industria: Biotechnology

P/B i: 13.17

Deuda / Patrimonio i: 1.92

Margen operativo: -48.72%

Margen neto: -49.91%

ROE i: -

ROIC: -

Salud financiera

Puntaje12 / 20

Deuda / Patrimonio: 1.92

Ratio corriente: 5.10

Ratio rápido: 4.92

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Koenig Scott

Transacción: 05/19/2026

COMPRA

Cambio

+3,750

Precio

Not reported

Presentación

05/20/2026

Tipo

COMPRA

Koenig Scott

Transacción: 05/19/2026

COMPRA

Cambio

+22,000

Precio

$4.52

Presentación

05/20/2026

Tipo

COMPRA

Ferrante Karen Jean

Transacción: 05/19/2026

COMPRA

Cambio

+3,750

Precio

Not reported

Presentación

05/20/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Koenig Scott	COMPRA	+3,750	Not reported	05/19/2026	05/20/2026
Koenig Scott	COMPRA	+22,000	$4.52	05/19/2026	05/20/2026
Ferrante Karen Jean	COMPRA	+3,750	Not reported	05/19/2026	05/20/2026
Ferrante Karen Jean	COMPRA	+22,000	$4.52	05/19/2026	05/20/2026
STUMP DAVID C	COMPRA	+3,750	Not reported	05/19/2026	05/20/2026
STUMP DAVID C	COMPRA	+22,000	$4.52	05/19/2026	05/20/2026
HURWITZ EDWARD	COMPRA	+3,750	Not reported	05/19/2026	05/20/2026
HURWITZ EDWARD	COMPRA	+22,000	$4.52	05/19/2026	05/20/2026
Chhabra Meenu	COMPRA	+3,750	Not reported	05/19/2026	05/20/2026
Chhabra Meenu	COMPRA	+22,000	$4.52	05/19/2026	05/20/2026
Liu Margaret	COMPRA	+3,750	Not reported	05/19/2026	05/20/2026
Liu Margaret	COMPRA	+22,000	$4.52	05/19/2026	05/20/2026
HEIDEN WILLIAM K	COMPRA	+3,750	Not reported	05/19/2026	05/20/2026
HEIDEN WILLIAM K	COMPRA	+22,000	$4.52	05/19/2026	05/20/2026
Jackson Scott Thomas	COMPRA	+3,750	Not reported	05/19/2026	05/20/2026
Jackson Scott Thomas	COMPRA	+22,000	$4.52	05/19/2026	05/20/2026
O'Brien Federica F.	COMPRA	+3,750	Not reported	05/19/2026	05/20/2026
O'Brien Federica F.	COMPRA	+22,000	$4.52	05/19/2026	05/20/2026
Ferrante Karen Jean	VENTA	-3,750	Not reported	05/18/2026	05/20/2026
Ferrante Karen Jean	COMPRA	+3,750	Not reported	05/18/2026	05/20/2026

Sobre la compañía

MacroGenics, Inc.

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

Fuente - Link

Competidores

CLNN CNTB CNTX COYA IFRX ORMP OVID STTK WHWK ZNTL

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Bank of America Corp DE Buys 564,094 Shares of MacroGenics, Inc. $MGNX

Bank of America Corp DE increased its stake in shares of MacroGenics, Inc. (NASDAQ: MGNX) by 30.7% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 2,401,814 shares of the biopharmaceutical company's stock after purchasing an additional 564,094 shares during the period. Bank of America

Defense World

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?

Here is how MacroGenics (MGNX) and CareDx (CDNA) have performed compared to their sector so far this year.

Zacks Investment Research

Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.

The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs.

Fool - Investing News

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

MacroGenics (MGNX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.57 per share a year ago.

Zacks Investment Research

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended June 30, 2026, and highlighted its recent corporate and pipeline progress.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-13	-0.57	-0.58	-0.01
2026-03-09	-0.42	-0.22	0.2
2025-11-12	-0.48	0.27	0.75
2025-08-14	-0.59	-0.57	0.02
2025-05-13	-0.61	-0.65	-0.04
2025-03-20	-0.23	-0.25	-0.02
2024-11-05	0.21	0.9	0.69
2024-08-07	-0.59	-0.89	-0.3
2024-05-09	-0.67	-0.84	-0.17
2024-03-07	-0.26	-0.75	-0.49
2023-11-06	-0.1055	-0.52	-0.4145
2023-08-09	-0.52	-0.36	0.16